Nimbus Thinks It Has “Non-First-Mover” Advantage In NASH

Working on an allosteric ACC inhibitor in NASH, Nimbus is not worried about being first to market but is willing to let others develop and prove out a pivotal development pathway in the indication, while it focuses on a unique mechanism of action.